Timothy Nicholls, MD
Internal Medicine · Shreveport, LANPI 1457314015
Payments from drug & device makers
Across 181 payments — averaging $14.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$428
- Pfizer$247
- AstraZeneca$193
- Lilly USA, LLC$190
- Abbott$187
- Johnson & Johnson$157
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,605100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 37 | $428 |
| Pfizer | 24 | $247 |
| AstraZeneca | 12 | $193 |
| Lilly USA, LLC | 12 | $190 |
| Abbott | 10 | $187 |
| Johnson & Johnson | 13 | $157 |
| Merck | 10 | $141 |
| Dexcom, Inc. | 7 | $133 |
| Boehringer Ingelheim | 6 | $108 |
| Phathom Pharmaceuticals, Inc. | 5 | $83 |
| Corcept Therapeutics | 3 | $79 |
| Novo Nordisk | 5 | $75 |
| E.r. Squibb & Sons, L.L.C. | 6 | $73 |
| Amgen | 4 | $61 |
| Xeris Pharmaceuticals, Inc. | 3 | $55 |
| Otsuka America Pharmaceutical, Inc. | 3 | $53 |
| AbbVie(2 entities) | 3 | $46 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $40 |
| Insulet Corporation | 2 | $37 |
| Abiomed | 2 | $37 |
| Astellas Pharma US Inc | 2 | $36 |
| Viatris Specialty LLC | 2 | $36 |
| Sanofi | 1 | $23 |
| Verona Pharma, Inc. | 1 | $19 |
| Vifor Pharma, Inc. | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Novartis | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
How this compares
$2,605 in reported general payments places this provider in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 141 | $133,610 |
| IngrezzaValbenazine Tosylate | 28 | $105,160 |
| MounjaroTirzepatide | 65 | $78,010 |
| OzempicSemaglutide | 59 | $60,222 |
| JardianceEmpagliflozin | 58 | $57,459 |
| XareltoRivaroxaban | 52 | $42,891 |
| TrulicityDulaglutide | 35 | $33,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $33,101 |
| FarxigaDapagliflozin Propanediol | 21 | $20,407 |
| RexultiBrexpiprazole | 12 | $18,195 |
| LinzessLinaclotide | 14 | $15,486 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 13 | $8,664 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $8,468 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $7,654 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $6,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $247 | $133,610141 claims |
| Lilly USA, LLCMounjaro, Trulicity | $190 | $111,793100 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Synjardy Xr | $108 | $72,73482 claims |
| Novo NordiskOzempic | $75 | $60,22259 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $428 | $45,70245 claims |
| Johnson & JohnsonXarelto | $157 | $42,89152 claims |
| AstraZenecaFarxiga | $193 | $20,40721 claims |
| AbbVieLinzess, Synthroid | $46 | $18,64561 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $53 | $18,19512 claims |
| NovartisEntresto | $13 | $4,95911 claims |
| Sanofi-aventis U.S. LLCLantus | $14 | $2,05917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Shreveport
- Deepika RallaShreveport$261K
- Maliha AgloriaShreveport$181K
- Bharat SachdevaShreveport$165K
- Rajan KhannaShreveport$59K
- Ishak MansiShreveport$53K
- Wendell WallShreveport$25K
- Attila BaloghShreveport$18K
- Ammar AlqaidShreveport$18K
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.